1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Nexalin Technology, Inc.

Nexalin Technology, Inc.

NXLIW
Nexalin Technology, Inc.US flagNASDAQ Capital Market
0.01
USD
+0.00
- -
283,160.00Market Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
1
- -
- -
- -
- -
Operating Margin (%)
-1,341.38
-4,177.7
-138.72
-5,143.48
-4,596.14
-2,781.69
-3,084.22
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-3
-6
-2
-5
-8
-8
-8
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,401.11
-4,218.93
-128.49
-4,197.56
-4,508.73
-2,725.76
-3,022.94
Working Capital
-1
-2
5
3
3
3
2
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
-2
-2
5
3
4
4
3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
19
21
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
5
4
3
Cash, Cash Equivalents & STI
4
4
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-88.97%
1.96%
Free Cash Flow
- -
47.11%
22.84%
Net Income, GAAP
- -
50.41%
8.08%
Sales/Revenue/Turnover
- -
163.2%
78.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Mark White
Full Time Employees
6
Sector
Healthcare
Industry
Medical - Devices
Address
1776 Yorktown Houston TX United States of America 77056
IPO Date
Sep 16, 2022
CIK
0001527352
Website
nexalin.com
Similar Companies
Bonesupport Holding AB (publ) (0RQO.L)
CellaVision AB (publ) (CLVSF)
SANUWAVE Health, Inc. (SNWV)
Surmodics, Inc. (SRDX)
Health Logic Interactive Inc. (CHYPF)
Genomtec S.A. (GMT.WA)
Business
Nexalin Technology, Inc. is a medical device firm dedicated to pioneering neurostimulation solutions for diverse mental health conditions across the United States, China, and other international markets. The company provides its Generation 1 device, a non-invasive, drug-free therapy employing bioelectronic technology to address anxiety and insomnia. This device utilizes a proprietary frequency-based waveform designed to engage deep brain structures associated with various mood and cognitive disorders. Expanding its therapeutic scope, Nexalin actively develops its Generation 2 (Gen-2 SYNC) and Generation 3 (Gen-3 Halo) medical devices, featuring an advanced 15-milliamp Deep Intracranial Frequency Stimulation (DIFS™) waveform. The Gen-2 device has secured regulatory approvals in markets including China, Brazil, Oman, and Israel for conditions such as insomnia, depression, and anxiety. These next-generation products are currently undergoing clinical trials and regulatory review, with positive outcomes reported for major depressive disorder, mild traumatic brain injury in veterans, gambling disorder, and showing promising results for Alzheimer's disease and dementia. The Gen-3 Halo headset is specifically engineered for convenient at-home use within a virtual clinic model, supervised by medical professionals. Established in 2010, the company maintains its operational hub in Houston, Texas.